Patient-Friendly Explanation
Ertugliflozin (Steglatro) is a type 2 diabetes medicine that helps the kidneys remove extra sugar through urine. This causes a modest amount of weight loss and a small drop in blood pressure. It belongs to a class of medicines called SGLT2 inhibitors and is taken once daily as a tablet.
Clinical Definition
Ertugliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by inhibiting renal glucose reabsorption, producing glycosuria of roughly 60-80 grams per day. This caloric loss typically yields 2-3 kg of weight reduction, with additional benefits on blood pressure and, in selected populations, cardiovascular and renal outcomes.
Why It Matters
SGLT2 inhibitors like ertugliflozin offer weight loss alongside diabetes control, which is why they are increasingly used in weight management. NuLifeCare Singapore can determine whether an SGLT2 inhibitor, alone or with other treatments, suits your metabolic profile and goals.